Get the Stockscreener App
8.13
0.86%
0.02
Cervomed Inc stock is traded at $8.13, with a volume of 1,584.
It is up +0.86% in the last 24 hours and down -7.12% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$8.15
Open:
$8.18
24h Volume:
1,584
Relative Volume:
0.00
Market Cap:
$75.49M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.4514
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
-4.64%
1M Performance:
-7.12%
6M Performance:
-3.24%
1Y Performance:
-39.11%
1-Day Range:
$8.12
$8.18
1-Week Range:
$8.05
$9.66
52-Week Range:
$1.80
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
8.1591 | 75.41M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
Trend analysis for CervoMed Inc. this weekTrade Entry Report & Low Drawdown Momentum Trade Ideas - newser.com
Analyzing recovery setups for CervoMed Inc. investors2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Is CervoMed Inc. a candidate for recovery playJobs Report & Free Technical Pattern Based Buy Signals - newser.com
What to do if you’re stuck in CervoMed Inc.2025 Momentum Check & Community Supported Trade Ideas - newser.com
Does CervoMed Inc. stock trade at a discount to peersIPO Watch & Advanced Swing Trade Entry Plans - newser.com
How to interpret RSI for CervoMed Inc. stockMarket Volume Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Will CervoMed Inc. outperform the market2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Using data tools to time your CervoMed Inc. exitJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Statistical indicators supporting CervoMed Inc.’s strength2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
Advanced analytics toolkit walkthrough for CervoMed Inc.2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
CervoMed (NASDAQ:CRVO) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Why CervoMed Inc. stock is rated strong buyShare Buyback & Low Drawdown Momentum Ideas - newser.com
CervoMed Unveils Promising Phase 2b Trial Results - TipRanks
CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - inkl
CervoMed shares jump after strong results in dementia drug trial - MSN
CervoMed stock jumps after new positive dementia drug results - Business Upturn
CervoMed stock soars after positive dementia treatment trial data - Investing.com
CervoMed Says Neflamapimod Shows Effective in Treating Dementia with Lewy Bodies Without Alzheimer's Overlap - MarketScreener
CervoMed (CRVO) Reveals Promising Phase 2b Trial Data for Dement - GuruFocus
CervoMed Inc. Reports Promising Phase 2b Trial Results for Neflamapimod in Dementia with Lewy Bodies - Quiver Quantitative
1.12‑pt CDR‑SB gain; 50% GFAP drop — CervoMed Phase 2b RewinD‑LB data show clinical–biomarker correlation - Stock Titan
CervoMed appoints Matthew Winton as chief commercial and business officer By Investing.com - Investing.com Canada
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer - GlobeNewswire
CervoMed Inc. Appoints Matthew Winton as Chief Commercial and Business Officer - MarketScreener
CervoMed appoints Matthew Winton as chief commercial and business officer - Investing.com
CervoMed appoints Matthew Winton, Ph.D., as chief commercial and business officer - MarketScreener
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - Sahm
Applying chart zones and confluence areas to CervoMed Inc.Trade Volume Summary & Daily Chart Pattern Signals - newser.com
Will CervoMed Inc. stock go up soon2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Will CervoMed Inc. (DP8) stock keep high P E multiples2025 Price Action Summary & Step-by-Step Trade Execution Guides - newser.com
Short Interest in CervoMed Inc. (NASDAQ:CRVO) Decreases By 31.7% - MarketBeat
What drives CervoMed Inc stock priceEarnings Revision Updates & Free Stock Education Platform for New Investors - earlytimes.in
How CervoMed Inc. (DP8) stock compares with market leaders2025 Trade Ideas & Consistent Growth Equity Picks - newser.com
Can a trend reversal in CervoMed Inc. lead to recoveryJuly 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Is CervoMed Inc. stock a buy in volatile markets2025 Dividend Review & Short-Term High Return Ideas - newser.com
Live market analysis of CervoMed Inc.Market Risk Analysis & Free Real-Time Market Sentiment Alerts - newser.com
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):